hypoparathyroidism |
Disease ID | 378 |
---|---|
Disease | hypoparathyroidism |
Manually Symptom | UMLS | Name(Total Manually Symptoms:51) C2697391 | rheumatoid arthritis C2697310 | sarcoidosis C2183399 | stupor C1963138 | hypertension C1963101 | encephalopathy C1521736 | parkinson's disease C1389280 | calcification of the basal ganglia C1389280 | basal ganglia calcification C1384665 | hemochromatosis C1368019 | paget's disease C1096308 | hypergonadism C0878544 | myocardiopathy C0878544 | cardiomyopathy C0752303 | urological manifestations C0752303 | urological manifestation C0751265 | learning disabilities C0740394 | hyperuricemia C0338437 | neurocysticercosis C0262548 | maternal hypothyroidism C0235270 | keratopathy C0162309 | adrenoleukomyeloneuropathy C0154162 | riedel's thyroiditis C0085681 | hyperphosphataemia C0039070 | syncopes C0038238 | steatorrhea C0038012 | spondylitis C0037763 | spasms C0037140 | b virus infection C0033975 | psychosis C0033860 | psoriasis C0033845 | pseudotumour cerebri C0029166 | oral manifestations C0028961 | oliguria C0027127 | thomsen's disease C0027066 | myoclonus C0023066 | laryngospasm C0020598 | hypocalcemia C0020438 | hypercalciuria C0020437 | hypercalcemia C0019202 | wilson's disease C0018802 | congestive heart failure C0018801 | heart failure C0018784 | sensorineural hearing loss C0010823 | cytomegalic inclusion disease C0008489 | choreiform movements C0007760 | cerebellar syndrome C0006845 | chronic mucocutaneous candidiasis C0006663 | calcinosis C0004364 | autoimmune diseases C0002063 | alkalosis C0000744 | mtp deficiency |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:13) C0020598 | hypocalcemia | 31 C1389280 | basal ganglia calcification | 3 C0154162 | riedel's thyroiditis | 2 C0019202 | wilson's disease | 2 C0020437 | hypercalcemia | 2 C0036202 | sarcoidosis | 2 C0004364 | autoimmune diseases | 2 C0018801 | heart failure | 2 C0006663 | calcinosis | 1 C1389280 | calcification of the basal ganglia | 1 C0878544 | cardiomyopathy | 1 C0033860 | psoriasis | 1 C0038238 | steatorrhea | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:1) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0020626 | calcitriol | D002117 | 32222-06-3 | hypoparathyroidism | MESH:D007011 | therapeutic | 2856045 |
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D007011 | calcijex | calcitriol | 0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D007011 | 11/16/2001 | calcijex | calcitriol | Management of hypocalcemia in patients undergoing chronic renal dialysis | The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75 | Labeling | B | - | - | - | Abbott | 02/16/2001 | FALSE' |